Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide As Firstline Options

Overview

Journal Pain Med

Specialties Critical Care
Neurology
Psychiatry

Date 2018 Aug 24

PMID 30137539

Citations 42

Authors

Timothy R Deer

Jason E Pope

Michael C Hanes

Gladstone C McDowell

Affiliations

Soon will be listed here.

Abstract

Objectives: To evaluate the evidence for morphine and ziconotide as firstline intrathecal (IT) analgesia agents for patients with chronic pain.

Methods: Medline was searched (through July 2017) for "ziconotide" or "morphine" AND "intrathecal" AND "chronic pain," with results limited to studies in human populations.

Results: The literature supports the use of morphine (based primarily on noncontrolled, prospective, and retrospective studies) and ziconotide (based on randomized controlled trials and prospective observational studies) as first-choice IT therapies. The 2016 Polyanalgesic Consensus Conference (PACC) guidelines recommended both morphine and ziconotide as firstline IT monotherapy for localized and diffuse chronic pain of cancer-related and non-cancer-related etiologies; however, one consensus point emphasized ziconotide use, unless contraindicated, as firstline IT therapy in patients with chronic non-cancer-related pain. Initial IT therapy choice should take into consideration individual patient characteristics (e.g., pain location, response to previous therapies, comorbid medical conditions, psychiatric history). Trialing is recommended to assess medication efficacy and tolerability. For both morphine and ziconotide, the PACC guidelines recommend conservative initial dosing strategies. Due to its narrow therapeutic window, ziconotide requires careful dose titration. Ziconotide is contraindicated in patients with a history of psychosis. IT morphine administration may be associated with serious side effects (e.g., respiratory depression, catheter tip granuloma), require dose increases, and cause dependence over time.

Conclusion: Based on the available evidence, morphine and ziconotide are recommended as firstline IT monotherapy for cancer-related and non-cancer-related pain. The choice of first-in-pump therapy should take into consideration patient characteristics and the advantages and disadvantages of each medication.

Citing Articles

Systemic antihyperalgesic effect of a novel conotoxin from in an inflammatory pain model.

Lopez-Carrillo J, Bernaldez-Sarabia J, Pawar T, Jimenez S, Duenas S, Figueroa-Montiel A Front Pain Res (Lausanne). 2025; 5:1500789.

PMID: 39925365 PMC: 11802583. DOI: 10.3389/fpain.2024.1500789.

Preclinical Efficacy and Proteomic Prediction of Molecular Targets for s-cal14.1b and s-cal14.2b Conotoxins with Antitumor Capacity in Xenografts of Malignant Pleural Mesothelioma.

Luna-Nophal A, Diaz-Castillo F, Izquierdo-Sanchez V, Velazquez-Fernandez J, Orozco-Morales M, Lara-Mejia L Mar Drugs. 2025; 23(1.

PMID: 39852534 PMC: 11767107. DOI: 10.3390/md23010032.

The conotoxin Contulakin-G reverses hypersensitivity observed in rodent models of cancer-induced bone pain without inducing tolerance or motor disturbance.

Martin L, Almuslim M, Ismail K, Ibrahim M, Moutal A, Cheng K Pain. 2024; 166(2):376-387.

PMID: 39297754 PMC: 11723812. DOI: 10.1097/j.pain.0000000000003391.

Structural information in therapeutic peptides: Emerging applications in biomedicine.

Iglesias V, Barcenas O, Pintado-Grima C, Burdukiewicz M, Ventura S FEBS Open Bio. 2024; 15(2):254-268.

PMID: 38877295 PMC: 11788753. DOI: 10.1002/2211-5463.13847.

A comprehensive review on ziconotide.

Lin J, Chen S, Butt U, Yan M, Wu B Heliyon. 2024; 10(10):e31105.

PMID: 38779019 PMC: 11110537. DOI: 10.1016/j.heliyon.2024.e31105.

References

Fisher R, Hassenbusch S, Krames E, Leong M, Minehart M, Prager J . A consensus statement regarding the present suggested titration for prialt (ziconotide). Neuromodulation. 2011; 8(3):153-4. DOI: 10.1111/j.1525-1403.2005.05232.x. View

Hamza M, Doleys D, Wells M, Weisbein J, Hoff J, Martin M . Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med. 2012; 13(10):1304-13. DOI: 10.1111/j.1526-4637.2012.01451.x. View

Deer T, Chapple I, Classen A, Javery K, Stoker V, Tonder L . Intrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for Low Back Pain. Pain Med. 2004; 5(1):6-13. DOI: 10.1111/j.1526-4637.2004.04011.x. View

Horazeck C, Huh A, Huh B . Acute rhabdomyolysis in a patient with long-term exposure to intrathecal ziconotide: a case report. Pain Pract. 2015; 15(3):E34-9. DOI: 10.1111/papr.12273. View

Duarte R, Raphael J, Southall J, Baker C, Hanu-Cernat D . Intrathecal inflammatory masses: is the yearly opioid dose increase an early indicator?. Neuromodulation. 2011; 13(2):109-13. DOI: 10.1111/j.1525-1403.2009.00259.x. View

Raffaeli W, Sarti D, Demartini L, Sotgiu A, Bonezzi C . Italian registry on long-term intrathecal ziconotide treatment. Pain Physician. 2011; 14(1):15-24. View

Deer T, Rauck R, Kim P, Saulino M, Wallace M, Grigsby E . Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM). Pain Pract. 2017; 18(2):230-238. DOI: 10.1111/papr.12599. View

Pope J, Deer T . Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability. Neuromodulation. 2015; 18(5):414-20. DOI: 10.1111/ner.12274. View

Anderson V, Burchiel K, Cooke B . A Prospective, Randomized Trial of Intrathecal Injection vs. Epidural Infusion in the Selection of Patients for Continuous Intrathecal Opioid Therapy. Neuromodulation. 2011; 6(3):142-52. DOI: 10.1046/j.1525-1403.2003.03023.x. View

10.

McNicol E, Horowicz-Mehler N, Fisk R, Bennett K, Gialeli-Goudas M, Chew P . Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003; 4(5):231-56. DOI: 10.1016/s1526-5900(03)00556-x. View

11.

Rauck R, Deer T, Rosen S, Padda G, Barsa J, Dunbar E . Accuracy and efficacy of intrathecal administration of morphine sulfate for treatment of intractable pain using the Prometra(®) Programmable Pump. Neuromodulation. 2011; 13(2):102-8. DOI: 10.1111/j.1525-1403.2009.00257.x. View

12.

Webster L, Fisher R, Charapata S, Wallace M . Long-term intrathecal ziconotide for chronic pain: an open-label study. J Pain Symptom Manage. 2008; 37(3):363-72. DOI: 10.1016/j.jpainsymman.2008.02.016. View

13.

Rauck R, Cherry D, Boyer M, Kosek P, Dunn J, Alo K . Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain. 2003; 4(8):441-7. DOI: 10.1067/s1526-5900(03)00730-2. View

14.

Prager J . Neuraxial medication delivery: the development and maturity of a concept for treating chronic pain of spinal origin. Spine (Phila Pa 1976). 2002; 27(22):2593-605; discussion 2606. DOI: 10.1097/01.BRS.0000032243.78028.84. View

15.

Ellis D, Dissanayake S, McGuire D, Charapata S, Staats P, Wallace M . Continuous Intrathecal Infusion of Ziconotide for Treatment of Chronic Malignant and Nonmalignant Pain Over 12 Months: A Prospective, Open-label Study. Neuromodulation. 2011; 11(1):40-9. DOI: 10.1111/j.1525-1403.2007.00141.x. View

16.

Follett K, Hitchon P, Piper J, Kumar V, Clamon G, Jones M . Response of intractable pain to continuous intrathecal morphine: a retrospective study. Pain. 1992; 49(1):21-25. DOI: 10.1016/0304-3959(92)90183-C. View

17.

Prusik J, Argoff C, Peng S, Pilitsis J . Use of Low Dose Ziconotide as First-Line Intrathecal Monotherapy. Neuromodulation. 2016; 20(4):386-391. DOI: 10.1111/ner.12486. View

18.

Bruel B, Burton A . Intrathecal Therapy for Cancer-Related Pain. Pain Med. 2016; 17(12):2404-2421. PMC: 5654346. DOI: 10.1093/pm/pnw060. View

19.

Brogan S, Winter N, Okifuji A . Prospective Observational Study of Patient-Controlled Intrathecal Analgesia: Impact on Cancer-Associated Symptoms, Breakthrough Pain Control, and Patient Satisfaction. Reg Anesth Pain Med. 2015; 40(4):369-75. DOI: 10.1097/AAP.0000000000000251. View

20.

Zhang Y, Ahmed S, Vo T, Hilaire K, Houghton M, Cohen A . Increased pain sensitivity in chronic pain subjects on opioid therapy: a cross-sectional study using quantitative sensory testing. Pain Med. 2014; 16(5):911-22. DOI: 10.1111/pme.12606. View